Intraoperative radiotherapy with the Intrabeam® device for the treatment of resectable pancreatic adenocarcinoma

• Published in: Cirugia española (English ed.) Vol. 96; no. 8; pp. 482 - 487
• Main Authors: Rahy-Martín, Aida Cristina, Cruz-Benavides, Francisco, Sánchez-Lauro, Mar, Rodríguez-Méndez, Álvaro, San Miguel, Íñigo, Lara, Pedro, Marchena-Gómez, Joaquín
• Format: Journal Article
• Language: English
• Published: 01.10.2018
• ISSN: 2173-5077
• DOI: 10.1016/j.ciresp.2018.04.014

INTRODUCTIONThe application of intraoperative radiation therapy to the tumor bed after resection of pancreatic cancer has been shown to be beneficial in the local control of the disease. The objective of this study was to evaluate the preliminary outcomes after the application of a single intraoperative dose to the tumor bed with a new intraoperative radiotherapy device (Intrabeam®) in terms of viability, safety and short-term results. METHODSWe studied 5 patients who underwent pancreaticoduodenectomy for resectable pancreatic cancer in which a radiotherapy boost (5Gy) was intraoperatively applied to the tumoral bed using the portable Intrabeam® device, a low-energy point-source X-ray. Postoperative complications, hospital stay and mortality, recurrences and short-term survival were analyzed. RESULTSMean patient age was 68 years. All patients had a T3-stage tumor and one of them N1. In 3 patients, R0 resection was performed, while R1 resection was conducted in 2. Perioperative mortality was 0%. The only complications included delayed gastric emptying and postoperative hemorrhage. There were no pancreatic fistulas. During follow-up (mean: 11.2 months), there was a relapse in the patient who had undergone R1 resection. CONCLUSIONSThe application of radiotherapy with the Intrabeam® device in selected patients has not resulted in increased perioperative morbidity or mortality; therefore, this is a safe procedure for the treatment of resectable cancer.